EPO and Renal insufficiency: One last story to put things into perspective recalled by John is that Dr. George Rathmann, who headed Amgen at the time of the EPO trial, was diagnosed with myeloma later in life and eventually developed renal failure and was the beneficiary of his own company’s product [40].